1. Home
  2. BGY vs EDIT Comparison

BGY vs EDIT Comparison

Compare BGY & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Blackrock Enhanced International Dividend Trust

BGY

Blackrock Enhanced International Dividend Trust

SELL

Current Price

$5.29

Market Cap

508.3M

Sector

Finance

ML Signal

SELL

Logo Editas Medicine Inc.

EDIT

Editas Medicine Inc.

HOLD

Current Price

$1.90

Market Cap

422.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BGY
EDIT
Founded
2007
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
508.3M
422.3M
IPO Year
N/A
2016

Fundamental Metrics

Financial Performance
Metric
BGY
EDIT
Price
$5.29
$1.90
Analyst Decision
Buy
Analyst Count
0
13
Target Price
N/A
★ $6.10
AVG Volume (30 Days)
304.9K
★ 2.2M
Earning Date
01-01-0001
11-09-2026
Dividend Yield
★ 7.41%
N/A
EPS Growth
N/A
★ 37.50
EPS
★ N/A
N/A
Revenue
N/A
★ $31,937,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 132.64
52 Week Low
$5.19
$1.66
52 Week High
$6.23
$3.94

Technical Indicators

Market Signals
Indicator
BGY
EDIT
Relative Strength Index (RSI) 39.72 N/A
Support Level $5.28 N/A
Resistance Level $5.85 N/A
Average True Range (ATR) 0.11 0.00
MACD 0.00 0.00
Stochastic Oscillator 3.03 0.00

Price Performance

Historical Comparison
BGY
EDIT

About BGY Blackrock Enhanced International Dividend Trust

Blackrock Enhanced International Dividend Trust is a diversified closed-end management investment company. Its primary investment objective is to provide current income and current gains, with a secondary objective of long-term capital appreciation. The Trust invests the majority of its net assets in dividend-paying equity securities issued by non-U.S. companies of any market capitalization, with a key focus on securities of large capitalization companies. It invests directly in such securities or synthetically through the use of derivatives.

About EDIT Editas Medicine Inc.

Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary gene editing platform based on CRISPR technology and continues to expand its capabilities. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1). The company has a single operating segment, which is the business of developing and commercializing gene editing technology.

Share on Social Networks: